Research Progress of Relationship Between CSN and Malignant Tumor_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 SUNLi-sha , CHENGuang-lei , LIUXu-hong , WEILiang , ZHOUYi-zhen ,  CHENBo

Department of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China;

Corresponding author：

CHENBo, Email: chbyxl@163.com

Keywords：

Constitutive photomorphogenesis 9 signalosome; Malignant tumor; Relationship

DOI：

10.7507/1007-9424.20150097

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the research progress of constitutive photomorphogenesis 9 signalosome (CSN) in malignant tumor in recent years. Methods Literatures about the relationship between CSN and maglinant tumor which were published in recent years were collected to make a review. Results Many malignant tumors were found to have high expression level of CSN, and CSN could degrade various tumor suppressor genes, such as p53 gene, mainly through regulating the ubiquitin protein degradation pathway, which played an role in promoting tumor growth. CSN5 was the deneddylation active center of CSN, and the activity of CSN was based on the integrity of CSN, which meant CSN6 (CSN core scaffold structure) have to exist. Current study found that CSN6 could promote tumorigenesis and development through a variety of signaling pathways, and CSN5 was mainly involved in cell cycle regulation and DNA damage repair to promote tumor growth. Conclusions The research of CSN in malignant tumors has lay a foundation of targeted therapies for cancer. However, the specific function of each of its subunit still remains unclear, and its upstream regulatory factors also need to be further explored.

Citation： SUNLi-sha, CHENGuang-lei, LIUXu-hong, WEILiang, ZHOUYi-zhen, CHENBo. Research Progress of Relationship Between CSN and Malignant Tumor. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(3): 361-364. doi: 10.7507/1007-9424.20150097 Copy

1.	Wei N, Deng XW. COP9:a new genetic locus involved in light-regulated development and gene expression in arabidopsis. Plant Cell, 1992, 4(12):1507-1518.
2.	Wei N, Chamovitz DA, Deng XW. Arabidopsis COP9 is a compo-nent of a novel signaling complex mediating light control of develo-pment. Cell, 1994, 78(1):117-124.
3.	Lee MH, Zhao R, Phan L, et al. Roles of COP9 signalosome in cancer. Cell Cycle, 2011, 10(18):3057-3066.
4.	Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest, 2011, 121(3):851-865.
5.	Choi HH, Gully C, Su CH, et al. COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ.Oncogene, 2011, 30(48):4791-4801.
6.	Nezames CD, Deng XW. The COP9 signalosome:its regulation of cullin-based E3 ubiquitin ligases and role in photomorphogenesis. Plant Physiol, 2012, 160(1):38-46.
7.	Wang W, Tang M, Zhang L, et al. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer. Jpn J Clin Oncol, 2013, 43(12):1170-1176.
8.	陈波, 金锋, 张磊, 等. CSN6对人乳腺癌细胞增殖的影响. 解剖科学进展, 2010, 16(3): 223-225.
9.	Xue Y, Chen J, Choi HH, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle, 2012, 11(22):4181-4190.
10.	Iyer SV, Iwakuma T. A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6. Cell Cycle, 2012, 11(22):4112.
11.	Pan Y, Zhang Q, Atsaves V, et al. Suppression of jab1/CSN5 induces radio-and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene, 2013, 32(22):2756-2766.
12.	Birol M, Echalier A. Structure and function of MPN (Mpr1/Pad1 N-terminal) domain-containing proteins. Curr Protein Pept Sci, 2014, 15(5):504-517.
13.	Sharon M, Mao H, Boeri Erba E, et al. Symmetrical modularity of the COP9 signalosome complex suggests its multifunctionality. Structure, 2009, 17(1):31-40.
14.	Kotiguda GG, Weinberg D, Dessau M, et al. The organization of a CSN5-containing subcomplex of the COP9 signalosome. J Biol Chem, 2012, 287(50):42031-42041.
15.	Gusmaroli G, Figueroa P, Serino G, et al. Role of the MPN subunits in COP9 signalosome assembly and activity, and their regulatory interaction with arabidopsis cullin3-based E3 ligases. Plant Cell, 2007, 19(2):564-581.
16.	Zhang H, Gao ZQ, Wang WJ, et al. The crystal structure of the MPN domain from the COP9 signalosome subunit CSN6. FEBS Lett, 2012, 586(8):1147-1153.
17.	Pick E, Golan A, Zimbler JZ, et al. The minimal deneddylase core of the COP9 signalosome excludes the Csn6 MPN-domain. PLoS One, 2012, 7(8):e43980.
18.	Echalier A, Pan Y, Birol M, et al. Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A, 2013, 110(4):1273-1278.
19.	Duan W, Gao L, Wu X, et al. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res, 2006, 312(17):3370-3378.
20.	Hetfeld BK, Peth A, Sun XM, et al. The COP9 signalosome-mediated deneddylation is stimulated by caspases during apoptosis. Apoptosis, 2008, 13(2):187-195.
21.	Richardson KS, Zundel W. The emerging role of the COP9 signalosome in cancer. Mol Cancer Res, 2005, 3(12):645-653.
22.	Mahalingam S, Ayyavoo V, Patel M, et al. HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci U S A, 1998, 95(7):3419-3424.
23.	Chen B, Zhao R, Su CH, et al. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle, 2012, 11(24):4633-4641.
24.	Inuzuka H, Fukushima H, Shaik S, et al. Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget, 2010, 1(7):685-690.
25.	Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3sigma and other proteins. Semin Cancer Biol, 2006, 16(3):225-234.
26.	Yang H, Wen YY, Zhao R, et al. DNA damage-induced protein14-3-3 sigma inhibits protein kinase B/Akt activation and suppressesAkt-activated cancer. Cancer Res, 2006, 66(6):3096-3105.
27.	Yang HY, Wen YY, Chen CH, et al. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol, 2003, 23(20):7096-7107.
28.	Xu XY, Wang WQ, Zhang L, et al. Clinical implications of p57 KIP2 expression in breast cancer. Asian Pac J Cancer Prev, 2012, 13(10):5033-5036.
29.	Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci, 2001, 58(12-13):1907-1922.
30.	Zhao R, Yang HY, Shin J, et al. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle, 2013, 12(6):935-943.
31.	Chun Y, Lee M, Park B, et al. CSN5/JAB1 interacts with the centromeric components CENP-T and CENP-W and regulates their proteasome-mediated degradation. J Biol Chem, 2013, 288(38):27208-27219.
32.	Zhang XC, Chen J, Su CH, et al. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem, 2008, 103(4):1219-1230.
33.	Pan Y, Wang M, Bu X, et al. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC Cancer, 2013, 13:323.
34.	Xiao S, Li D, Zhu HQ, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A, 2006, 103(44):16448-16453.
35.	Xu GP, Zhang ZL, Xiao S, et al. Rig-G negatively regulates SCF-E3 ligase activities by disrupting the assembly of COP9 signalosome complex. Biochem Biophys Res Commun, 2013, 432(3):425-430.
36.	Wei S, Chu PC, Chuang HC, et al. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. PLoS One, 2012, 7(10):e47298.

1. Wei N, Deng XW. COP9:a new genetic locus involved in light-regulated development and gene expression in arabidopsis. Plant Cell, 1992, 4(12):1507-1518.
2. Wei N, Chamovitz DA, Deng XW. Arabidopsis COP9 is a compo-nent of a novel signaling complex mediating light control of develo-pment. Cell, 1994, 78(1):117-124.
3. Lee MH, Zhao R, Phan L, et al. Roles of COP9 signalosome in cancer. Cell Cycle, 2011, 10(18):3057-3066.
4. Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest, 2011, 121(3):851-865.
5. Choi HH, Gully C, Su CH, et al. COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σ.Oncogene, 2011, 30(48):4791-4801.
6. Nezames CD, Deng XW. The COP9 signalosome:its regulation of cullin-based E3 ubiquitin ligases and role in photomorphogenesis. Plant Physiol, 2012, 160(1):38-46.
7. Wang W, Tang M, Zhang L, et al. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer. Jpn J Clin Oncol, 2013, 43(12):1170-1176.
8. 陈波, 金锋, 张磊, 等. CSN6对人乳腺癌细胞增殖的影响. 解剖科学进展, 2010, 16(3): 223-225.
9. Xue Y, Chen J, Choi HH, et al. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53. Cell Cycle, 2012, 11(22):4181-4190.
10. Iyer SV, Iwakuma T. A novel link between the HER2-Akt and MDM2-p53 pathways via CSN6. Cell Cycle, 2012, 11(22):4112.
11. Pan Y, Zhang Q, Atsaves V, et al. Suppression of jab1/CSN5 induces radio-and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene, 2013, 32(22):2756-2766.
12. Birol M, Echalier A. Structure and function of MPN (Mpr1/Pad1 N-terminal) domain-containing proteins. Curr Protein Pept Sci, 2014, 15(5):504-517.
13. Sharon M, Mao H, Boeri Erba E, et al. Symmetrical modularity of the COP9 signalosome complex suggests its multifunctionality. Structure, 2009, 17(1):31-40.
14. Kotiguda GG, Weinberg D, Dessau M, et al. The organization of a CSN5-containing subcomplex of the COP9 signalosome. J Biol Chem, 2012, 287(50):42031-42041.
15. Gusmaroli G, Figueroa P, Serino G, et al. Role of the MPN subunits in COP9 signalosome assembly and activity, and their regulatory interaction with arabidopsis cullin3-based E3 ligases. Plant Cell, 2007, 19(2):564-581.
16. Zhang H, Gao ZQ, Wang WJ, et al. The crystal structure of the MPN domain from the COP9 signalosome subunit CSN6. FEBS Lett, 2012, 586(8):1147-1153.
17. Pick E, Golan A, Zimbler JZ, et al. The minimal deneddylase core of the COP9 signalosome excludes the Csn6 MPN-domain. PLoS One, 2012, 7(8):e43980.
18. Echalier A, Pan Y, Birol M, et al. Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A, 2013, 110(4):1273-1278.
19. Duan W, Gao L, Wu X, et al. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res, 2006, 312(17):3370-3378.
20. Hetfeld BK, Peth A, Sun XM, et al. The COP9 signalosome-mediated deneddylation is stimulated by caspases during apoptosis. Apoptosis, 2008, 13(2):187-195.
21. Richardson KS, Zundel W. The emerging role of the COP9 signalosome in cancer. Mol Cancer Res, 2005, 3(12):645-653.
22. Mahalingam S, Ayyavoo V, Patel M, et al. HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci U S A, 1998, 95(7):3419-3424.
23. Chen B, Zhao R, Su CH, et al. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6. Cell Cycle, 2012, 11(24):4633-4641.
24. Inuzuka H, Fukushima H, Shaik S, et al. Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget, 2010, 1(7):685-690.
25. Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3sigma and other proteins. Semin Cancer Biol, 2006, 16(3):225-234.
26. Yang H, Wen YY, Zhao R, et al. DNA damage-induced protein14-3-3 sigma inhibits protein kinase B/Akt activation and suppressesAkt-activated cancer. Cancer Res, 2006, 66(6):3096-3105.
27. Yang HY, Wen YY, Chen CH, et al. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol, 2003, 23(20):7096-7107.
28. Xu XY, Wang WQ, Zhang L, et al. Clinical implications of p57 KIP2 expression in breast cancer. Asian Pac J Cancer Prev, 2012, 13(10):5033-5036.
29. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci, 2001, 58(12-13):1907-1922.
30. Zhao R, Yang HY, Shin J, et al. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle, 2013, 12(6):935-943.
31. Chun Y, Lee M, Park B, et al. CSN5/JAB1 interacts with the centromeric components CENP-T and CENP-W and regulates their proteasome-mediated degradation. J Biol Chem, 2013, 288(38):27208-27219.
32. Zhang XC, Chen J, Su CH, et al. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem, 2008, 103(4):1219-1230.
33. Pan Y, Wang M, Bu X, et al. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC Cancer, 2013, 13:323.
34. Xiao S, Li D, Zhu HQ, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A, 2006, 103(44):16448-16453.
35. Xu GP, Zhang ZL, Xiao S, et al. Rig-G negatively regulates SCF-E3 ligase activities by disrupting the assembly of COP9 signalosome complex. Biochem Biophys Res Commun, 2013, 432(3):425-430.
36. Wei S, Chu PC, Chuang HC, et al. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. PLoS One, 2012, 7(10):e47298.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress of Relationship Between CSN and Malignant Tumor

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content